Tyrosine kinase inhibitorFDA-approvedFirst-line
Gefitinib
How it works
Blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing them from growing and dividing.
Cancer types
Lung Cancer— EGFR-mutated
Efficacy
In clinical trials, gefitinib improved response rates and progression-free survival in patients with EGFR-mutated non-small cell lung cancer.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Nanoparticle Formulation Enhances Cancer Drug's Effectiveness | Lung Cancer | lab-study | The nanosuspension showed a 33.8% higher inhibition rate than the physical mixture after 72 h. | Source → |
| Combining Traditional Chinese Medicine with Gefitinib May Help Treat Lung Cancer | Lung Cancer | lab-study | The combination therapy suppressed both the clonogenic ability and the combined processes of migration and proliferation in H1975 cells. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.